Literature DB >> 10347984

Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study.

V Salomaa1, C Matei, N Aleksic, L Sansores-Garcia, A R Folsom, H Juneja, L E Chambless, K K Wu.   

Abstract

BACKGROUND: Small amounts of soluble thrombomodulin in plasma are thought to reflect endothelial damage. In a case-cohort study, we examined whether soluble thrombomodulin is a predictor of incident coronary heart disease and carotid artery atherosclerosis.
METHODS: The study population consisted of 14,170 black and white participants from the Atherosclerosis Risk in Communities (ARIC) study, who did not have cardiovascular disease at the start of the study and who we followed up for 6 years. After appropriate exclusions, we analysed 258 cases of incident coronary heart disease and 449 cases of carotid atherosclerosis. A stratified random sample of 753 individuals from the ARIC cohort was used as the comparison group. We used EIA to measure soluble thrombomodulin in plasma samples from both groups. For the analysis, we used quintiles of soluble thrombomodulin concentrations (< 24.7, 24.8-30.6, 30.7-40.2, 40.3-55.2, and > or = 55.3 ng/mL).
FINDINGS: Soluble thrombomodulin showed a strong, graded, inverse association with incident coronary heart disease (p=0.005). The adjusted rate ratio of the highest quintile of soluble thrombomodulin compared with the lowest quintile was 0.29 (95% CI 0.15-0.57). The association with carotid atherosclerosis, however, tended to be positive, especially among white participants (odds ratio 2.94 [1.15-7.51] for highest vs lowest quintile). The relation of soluble thrombomodulin to incident coronary heart disease and carotid atherosclerosis was dependent on factor VIII coagulant activity (p=0.06 and 0.003, respectively).
INTERPRETATION: The prospective association of soluble thrombomodulin with incident coronary heart disease differs from its cross-sectional association with carotid atherosclerosis. In healthy people, plasma concentrations of soluble thrombomodulin may reflect endothelial expression of thrombomodulin. High concentration of soluble thrombomodulin may be associated with decreased risk of coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347984     DOI: 10.1016/s0140-6736(98)09057-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  31 in total

Review 1.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

2.  Gene expression profiling of coronary artery disease and its relation with different severities.

Authors:  Shiridhar Kashyap; Sudeep Kumar; Vikas Agarwal; Durga P Misra; Shubha R Phadke; Aditya Kapoor
Journal:  J Genet       Date:  2018-09       Impact factor: 1.166

3.  Does the oxidation of methionine in thrombomodulin contribute to the hypercoaguable state of smokers and diabetics?

Authors:  Wesley E Stites; Jeffrey W Froude
Journal:  Med Hypotheses       Date:  2006-10-24       Impact factor: 1.538

4.  Soluble thrombomodulin as a predictor of type 2 diabetes: results from the MONICA/KORA Augsburg case-cohort study, 1984-1998.

Authors:  B Thorand; J Baumert; C Herder; C Meisinger; W Koenig
Journal:  Diabetologia       Date:  2006-12-29       Impact factor: 10.122

Review 5.  Hypercoagulable states and strokes.

Authors:  Nena Matijevic; Kenneth K Wu
Journal:  Curr Atheroscler Rep       Date:  2006-07       Impact factor: 5.113

6.  Does administration of eicosapentaenoic acid increase soluble thrombomodulin level in statin-treated patients with stable coronary artery disease?

Authors:  Shigemasa Tani; Rei Matsuo; Atsushi Hirayama
Journal:  Heart Vessels       Date:  2018-08-24       Impact factor: 2.037

7.  Elevation of the soluble thrombomodulin levels is associated with inflammation after percutaneous coronary interventions.

Authors:  Ting-Hsing Chao; Yi-Heng Li; Wei-Chuan Tsai; Jyh-Hong Chen; Ping-Yen Liu; Liang-Min Tsai
Journal:  Clin Cardiol       Date:  2004-07       Impact factor: 2.882

8.  Assessment of coronary heart disease risk by combined analysis of coagulation factors.

Authors:  Nena Aleksic; Yao-Wei W Wang; Chul Ahn; Harinder S Juneja; Aaron R Folsom; Kenneth K Wu
Journal:  Atherosclerosis       Date:  2008-03-14       Impact factor: 5.162

9.  Common genetic risk factors for venous thrombosis in the Chinese population.

Authors:  Liang Tang; Hua-Fang Wang; Xuan Lu; Xiao-Rong Jian; Bi Jin; Hong Zheng; Yi-Qing Li; Qing-Yun Wang; Tang-Chun Wu; Huan Guo; Hui Liu; Tao Guo; Jian-Ming Yu; Rui Yang; Yan Yang; Yu Hu
Journal:  Am J Hum Genet       Date:  2013-01-17       Impact factor: 11.025

10.  Hemostatic factors and subclinical brain infarction in a community-based sample: the ARIC study.

Authors:  R F Gottesman; C Cummiskey; L Chambless; K K Wu; N Aleksic; A R Folsom; A R Sharrett
Journal:  Cerebrovasc Dis       Date:  2009-10-16       Impact factor: 2.762

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.